131220 — Daihan Scientific Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩44bn
- KR₩44bn
- KR₩74bn
- 91
- 69
- 21
- 69
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 5,712 | 7,718 | 9,340 | 10,115 | 12,811 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,428 | 5,525 | 6,385 | 6,247 | 6,751 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 27,992 | 28,903 | 36,289 | 38,963 | 44,424 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 15,143 | 14,683 | 17,091 | 18,980 | 18,153 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 44,444 | 44,962 | 54,920 | 59,453 | 63,996 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8,651 | 9,733 | 13,328 | 11,922 | 14,709 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 16,203 | 15,742 | 22,295 | 23,021 | 24,799 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 28,241 | 29,220 | 32,625 | 36,432 | 39,197 |
Total Liabilities & Shareholders' Equity | 44,444 | 44,962 | 54,920 | 59,453 | 63,996 |
Total Common Shares Outstanding |